As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.
Like the small sweets children will be collecting this weekend, John Healey’s first Budget brought initial excitement, but was followed by mild disappointment as the boxes of boring raisons were found to outnumber the chocolate bars.
AI-powered analysis of Phase 3 CHARM trial suggests that Brainomix non-contrast CT (NCCT) technology may help identify severe stroke patients more likely to benefit from CIRARA, supporting more precise patient selection and the design of future stroke trials.
This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.
Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.
Q3 UK biotech financing; Budget calls; early-stage funding gap; faster clinical trials; connecting Government and industry; digital and AI skills webinar
UK biotech venture capital investment reached £270 million, up 44% from £187 million in Q3 2025, according to new figures from the BioIndustry Association (“BIA”).
Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.
Industry leaders gathered at Discovery Park on 14 October for The Lab of the Future & Green Chemistry Innovation, an event exploring pharmaceutical AI, automation and green chemistry, with speakers urging the industry to unite to share learnings and knowledge.
NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.
Chris Molloy on investment for BIA members; TIME’s Best Inventions; MHRA 2030 Strategy; Rare disease medicines review; Party conferences; TechBio; and BIA's AGM
